U.S. markets closed

Recro Pharma, Inc. (REPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2400+0.1000 (+4.67%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.1400
Bid2.2500 x 1300
Ask2.2500 x 800
Day's Range2.1000 - 2.2600
52 Week Range1.4900 - 5.2900
Avg. Volume399,634
Market Cap104.416M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.6650
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Recro Pharma, Inc.
    PCRX: Lowering target price to $58.00PACIRA BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $58.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Zacks

    Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

    Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

    SAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc. (“BioCorRx”; OTCQB: BICX), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the expansion of the companies’ ongoing relationship with the si

  • GlobeNewswire

    Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS

    Acquisition Expands Recro’s Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast Scheduled for 11:00 a.m. Eastern on Thursday, August 19, 2021 EXTON, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies dev